Tiger Brokers

ProMIS Neurosciences FY2025 net loss rises to $40 million; R&D expenses more than tripled to $33 million

Reuters
Mar 25
ProMIS Neurosciences FY2025 net loss rises to $40 million; R&D expenses more than tripled to $33 million
  • FY2025 net loss totaled $39.7 million.
  • FY2025 research and development expenses more than tripled to $33.4 million on higher costs to run the PRECISE-AD trial.
  • FY2025 general and administrative expenses increased 9.68% to $6.8 million on higher employee headcount.
  • FY2025 cash was $6.1 million.
  • Neil Warma said enrollment in the PRECISE-AD Phase 1b trial was completed in FY2025 and PMN310 had no treatment-related serious adverse events reported to date.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProMIS Neurosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603250800OMX_____CNEWS_EN_GNW9678216_en) on March 25, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10